TREATMENT OPTIONS
Understand
Your Options
Know what treatment needs to achieve, what is available now, and what opportunity should be protected next.
Understand Your Treatment Path
Start with whether cure remains possible, then understand what treatment needs to achieve before exploring the options that may help achieve it.
Explore Treatment Options
START WITH CURE
Is There a Curative Opportunity?
Surgery is the main established curative-intent pathway for cholangiocarcinoma. The first treatment decision should therefore begin by determining whether all known cancer can be completely removed.
Think of surgery as a series of doors, not one door. If one door is closed, the next question is whether another curative pathway can still open.
The First Question
Before asking which treatment to use, first ask whether all known cancer can be completely removed.
Surgery is the main established curative-intent pathway for cholangiocarcinoma.
That makes resectability one of the first questions that should be resolved.
If the answer is uncertain or surgery has been ruled out, understand exactly why before assuming the curative pathway is closed.
Right Question Can all known cancer be completely removed with curative intent?
Specialist Surgical Assessment
Resectability is partly a technical judgement. The answer can depend on the surgeon, the centre and the capability available.
An oncology opinion, radiology report or multidisciplinary discussion is not the same as a direct surgical assessment by a surgeon experienced in cholangiocarcinoma.
If surgery has been ruled out, identify who made that decision and whether an experienced hepatobiliary surgeon has personally reviewed the imaging and anatomy.
Right Question Has an experienced cholangiocarcinoma surgeon personally reviewed my imaging and assessed whether complete removal is possible?
More Complex Surgery
“Not operable” can sometimes mean that the operation required is more complex than the one first considered.
Depending on tumour location and anatomy, surgery may involve major liver resection, bile duct reconstruction, a Whipple procedure, vascular reconstruction or other specialised techniques.
The important distinction is whether the cancer is biologically impossible to remove, or whether removal requires expertise or capability available elsewhere.
Right Question Does complete removal require surgical expertise or reconstruction available at a more specialised centre?
Prepare the Liver First
The issue may not be whether the tumour can be removed. It may be whether enough functioning liver would remain afterwards.
The liver left behind after surgery is called the future liver remnant. It must be large and healthy enough to support the body.
In selected patients, procedures such as portal vein embolisation or other liver-preparation strategies may increase the future liver remnant before major surgery.
Right Question Is the future liver remnant the barrier to surgery, and can that barrier be changed?
Can Treatment Change Resectability?
“Not removable today” does not always mean “not removable later”.
Treatment may reduce tumour burden, control disease or change the relationship between the tumour and critical structures.
Chemotherapy, radiation or locoregional treatment may therefore have another possible job beyond disease control: creating a future surgical opportunity.
A surgical decision made before treatment describes the disease at that point in time. If the disease changes, the surgical question may need to be asked again.
Right Question If this treatment works, what would need to change for surgery to become possible, and when will resectability be reassessed?
Transplant Pathway
Liver transplantation is a separate curative-intent pathway with highly specific entry criteria.
In selected cholangiocarcinoma situations, transplantation may form part of a specialist treatment pathway.
Eligibility depends on factors including disease location, extent, treatment protocol and the criteria used by the transplant centre.
It should therefore be considered as a distinct specialist assessment rather than assumed to be part of standard resectability assessment.
Right Question Does my disease fit a situation where a specialist transplant pathway should be assessed?
TREATMENT GOAL
What Does Treatment Need to Achieve?
A treatment is not the goal. It is a tool chosen to achieve a goal.
Before comparing treatments, know the job that needs to be done: pursue cure, create a new opportunity, control the disease, act on its biology, or protect your ability to keep treating.
Goal 1
Pursue Cure
Start with the highest-value outcome: can treatment remove or eliminate all known cancer?
Surgery is the main established curative-intent pathway for cholangiocarcinoma, with transplantation forming a separate specialist pathway for selected patients.
This is why curative opportunity should be assessed before the treatment plan settles into disease control alone.
If cure is possible now, the treatment plan should protect that opportunity.
Right Question Is this treatment plan pursuing a curative opportunity that exists now?
Goal 2
Create Opportunity
If cure is not possible today, treatment may still have the job of changing what becomes possible tomorrow.
Treatment may reduce tumour burden, control disease elsewhere, change the relationship to important structures or create the conditions for another procedure.
In selected patients, that may reopen a surgical or other curative-intent pathway.
The important point is to define the barrier before treatment starts so that everyone knows what change would matter.
Right Question What would this treatment need to change for a new treatment or curative opportunity to become possible?
Goal 3
Control Disease
When cure is not currently possible, disease control still needs a clearly defined job.
Treatment may aim to shrink the cancer, stop or slow growth, control disease in a particular area, reduce symptoms or delay progression.
Those are different goals. Knowing which one applies makes the later response easier to interpret.
It also determines what should happen if the treatment achieves more than expected.
Right Question What exactly are we asking this treatment to achieve?
Goal 4
Match the Biology
Where the cancer is matters. What is driving it can matter as well.
Cholangiocarcinoma is not one biological disease. Tumours can differ in their mutations, fusions, proteins, immune features and other biomarkers.
Testing may identify a biological feature that makes a targeted therapy, immunotherapy or clinical trial relevant.
The purpose of testing is therefore not simply to produce a report. It is to determine whether the biology creates an option.
Right Question What has been found in my cancer, and what treatment or trial opportunity does that finding create?
Goal 5
Preserve Treatment Ability
An option only remains an option while you are able to receive it.
Bile obstruction, infection, declining liver function, weight loss, muscle loss, treatment toxicity and reduced physical function can all affect whether treatment or a procedure remains possible.
Managing these problems is not separate from cancer treatment. It can help protect access to the next treatment, procedure or trial.
The treatment plan should therefore consider both what is being done to the cancer and what must be preserved in the patient.
Right Question What could make me unable to receive the next treatment or procedure, and what can we protect now?
CURATIVE PATHWAY
Surgery
Surgery aims to remove all known cancer while leaving enough healthy, functioning tissue for you to recover safely.
The key question is not simply whether someone has said “operable” or “inoperable”. Understand what is preventing complete removal, whether that barrier can be overcome, and whether the right surgical expertise has assessed it.
Resectability
Resectability asks whether all known cancer can be removed safely with an operation.
Tumour location, involvement of major blood vessels or bile ducts, disease elsewhere, liver reserve and the amount of healthy tissue that would remain can all affect that decision.
Surgical capability matters too. A tumour that cannot be removed with one operation or at one centre may require a more specialised approach.
Right Question What specifically makes my cancer resectable or unresectable, and which of those barriers could potentially change?
The Right Surgeon
The surgeon is part of the treatment capability.
Cholangiocarcinoma surgery may involve complex liver, pancreatic, biliary or vascular anatomy. Experience with the specific tumour location and operation therefore matters.
A multidisciplinary team can bring valuable expertise together, but an MDT discussion is not a substitute for direct assessment by the surgeon whose expertise is needed to determine whether the operation is technically possible.
If the answer is no or uncertain, another specialist surgical assessment may identify a different technical option.
Right Question Which surgeon personally reviewed my imaging, what experience do they have with this type of cholangiocarcinoma operation, and should another specialist surgical opinion be obtained?
Which Operation?
The operation is determined largely by where the cancer is and what structures must be removed to achieve complete resection.
Distal bile duct cancers may require a Whipple procedure. Intrahepatic and perihilar cancers may require liver resection, sometimes including an extended hepatectomy or complex bile duct reconstruction.
The operation is therefore not simply “surgery”. The anatomy determines what must be removed and reconstructed.
Right Question What operation would be required to remove all known cancer, and why is that the operation that fits my tumour location?
Blood Vessel Involvement
A tumour involving a major blood vessel can make surgery more difficult, but involvement does not by itself describe every technical possibility.
In selected patients, specialised teams may consider removing and reconstructing an involved blood vessel as part of the operation.
Whether that is appropriate depends on the vessel involved, the extent of disease, the operation required and the experience of the surgical team.
Right Question Is blood vessel involvement the barrier to surgery, and has reconstruction been assessed by a surgeon experienced in this type of operation?
Liver Reserve
Removing the cancer is only one side of liver surgery. Enough functioning liver must remain afterwards.
The liver that would remain after surgery is called the future liver remnant.
If the future liver remnant is too small, selected patients may undergo a liver-preparation procedure, such as portal vein embolisation, to encourage the liver that will remain to grow before surgery.
Right Question Is the future liver remnant limiting surgery, and can anything be done to increase the amount of functioning liver that would remain?
Reassess After Treatment
Resectability describes the disease at a particular point in time.
If treatment reduces tumour burden, controls disease elsewhere or changes the relationship between the tumour and critical structures, the surgical question may change.
A previous decision that surgery was not possible should therefore not automatically remain permanent if the disease meaningfully changes.
Right Question Has treatment changed the disease enough that resectability should now be assessed again?
Liver Transplant
Transplant is a separate curative-intent pathway with specific eligibility criteria.
In selected cholangiocarcinoma settings, specialist transplant programs may consider liver transplantation as part of a defined treatment protocol.
Eligibility depends on disease location, extent, prior treatment, protocol requirements and the transplant centre.
Right Question Does my disease fit a recognised transplant pathway, and should a specialist transplant centre assess it?
Treatment Terms
Loading…
PROTECT THE PATHWAY
Biliary Management
Bile needs a working path from the liver into the intestine. When that path is obstructed, pressure, jaundice, infection and declining liver function can interfere with treatment.
Think of the bile ducts as the drainage system of the liver. Find where flow is failing, restore the route, then make sure it continues to drain.
Why Bile Flow Matters
Bile is made in the liver and needs a clear route out.
When bile cannot drain normally, bilirubin can rise, jaundice and itching can develop, liver function can worsen and infection risk can increase.
Poor drainage can also delay or interrupt chemotherapy, procedures or surgery.
Biliary management is therefore not separate from cancer treatment. Keeping bile moving can help preserve the ability to continue treating.
Right Question Is poor bile flow affecting my liver function or delaying another treatment?
Find the Obstruction
Before fixing the drainage system, identify where the flow is being stopped.
Tumour, narrowing, inflammation, debris or a blocked stent can interfere with bile flow.
The location matters because different parts of the liver may drain through different ducts. Opening one pathway does not necessarily mean every obstructed area is draining.
The first practical job is therefore to identify the level and cause of obstruction and decide which ducts need drainage.
Right Question Where exactly is the obstruction, what is causing it, and which parts of my liver need to be drained?
Stent Plan
A stent opens a narrowed pathway. It still needs a plan for what happens afterwards.
Biliary stents may be plastic or self-expanding metal. Their expected duration, removability and suitability can differ.
The choice can depend on tumour location, expected duration of drainage, whether surgery remains possible, how the ducts are divided and what future procedures may be needed.
Stents can also block, migrate or stop draining effectively. New jaundice, itching, fever, dark urine, pale stools or worsening blood tests may indicate that drainage needs reassessment.
Right Question What stent do I have, why was it chosen, how will it be monitored, and when would it need to be checked, exchanged or replaced?
Is Enough Liver Draining?
Placing a stent or drain is not the endpoint. The endpoint is effective drainage.
Drainage may be internal, external or a combination of both, depending on where the obstruction sits and how the biliary system can be reached.
In complex obstruction, particularly where different ductal systems are separated, the important question is whether enough functioning liver is actually being decompressed.
Symptoms, bilirubin, liver tests and imaging can help show whether drainage is working.
Right Question Is enough functioning liver draining, and are my bilirubin and liver tests improving as expected?
Infection & Cholangitis
Cholangitis is infection within the biliary system and can become serious quickly.
It is often associated with impaired bile drainage.
Fever, chills, worsening abdominal pain, jaundice or sudden deterioration require urgent medical assessment.
Antibiotics may treat the infection, but if drainage remains impaired, the underlying drainage problem may also need urgent treatment.
Right Question Is this cholangitis being driven by poor drainage, and does the drainage problem need to be corrected as well as the infection?
ERCP or PTBD?
These are two different routes for reaching the biliary system.
ERCP approaches the bile ducts from inside the digestive tract. It may be used to assess obstruction, place or exchange a stent, restore drainage and sometimes obtain tissue or cell samples.
PTBD approaches the bile ducts through the skin and liver using image guidance. It may be used when ERCP cannot reach or drain the required ducts adequately.
The important issue is not which procedure sounds simpler. It is which route can achieve the drainage or access actually needed.
Right Question Which route gives the best access to the ducts that need drainage, and what exactly is the procedure intended to achieve?
Loading Ursodeoxycholic acid / UDCA / Urso…
IMAGE-GUIDED TREATMENT
Interventional Radiology
Interventional Radiology uses imaging to reach tumours, blood vessels and bile ducts directly. It can treat selected disease sites, support other treatments and sometimes change what becomes possible next.
Think of Interventional Radiology as working directly on the barrier. The job may be to reduce tumour burden, treat a difficult site, prepare the liver or solve a technical problem that is limiting another treatment.
What Can Interventional Radiology Change?
Interventional Radiology is not one treatment. It is a way of reaching a specific problem directly.
Imaging can guide needles, catheters and other instruments to tumours, blood vessels or bile ducts.
The purpose may be to treat a tumour locally, reduce tumour burden, prepare the liver, restore access or change something that is currently limiting another treatment.
The first decision is therefore not “Which IR procedure?” It is “What problem are we trying to change?”
Right Question Has an experienced interventional radiologist reviewed my imaging, and is there a specific problem they could treat that would create another option?
TACE
TACE uses the tumour's blood supply as the route for delivering treatment directly to it.
The important decision is whether tumour location, blood supply and disease pattern make TACE a useful local treatment.
Its purpose should be defined before treatment: local control, reduction of tumour burden, or changing what becomes possible afterwards.
Right Question What exactly are we asking TACE to achieve, and what would we reconsider if it works?
Y-90 / SIRT
Y-90 carries radiation through the tumour's blood supply so treatment is delivered from inside the liver.
The goal may be local control, reduction of tumour burden or changing the disease enough for another treatment to be reconsidered.
That makes the planned consequence of treatment as important as the technology itself.
Right Question What do we need Y-90 to change, and what option becomes possible if it achieves that?
Ablation
Ablation destroys a selected tumour where it sits rather than surgically removing it.
Different methods use different forms of energy. These include heat, freezing, electrical pulses and mechanical energy.
The key decision is whether a tumour's size, number and location make direct treatment technically useful, and which method best fits that anatomy.
Right Question Is any part of my disease suitable for ablation, which method best fits its size and location, and what would treating it change?
Prepare or Support Another Treatment
Sometimes Interventional Radiology is not treating the cancer as the final step. It is preparing the body or anatomy for what needs to happen next.
The procedure may address a technical barrier, prepare part of the liver, improve access or support another treatment pathway.
This is why the procedure should always be linked to a defined next decision rather than treated as an isolated intervention.
Right Question What future treatment is this procedure helping make safer, technically possible or more effective?
Can IR Reopen Surgery?
If Interventional Radiology changes the barrier, the surgical decision may need to change too.
The barrier may be tumour burden, a difficult tumour site, inadequate future liver volume or another technical problem.
If an interventional procedure changes that barrier, resectability should be reconsidered rather than allowing the original surgical decision to remain fixed.
Right Question Can this procedure change what is preventing surgery today, what exactly would need to change, and when will surgery be reassessed?
Treatment Terms
Loading…
SYSTEMIC TREATMENT
Chemotherapy
Chemotherapy travels through the bloodstream, allowing treatment to reach cancer in more than one place.
The drug name is not the starting point. First understand what systemic treatment needs to achieve, how its effect will be measured, and what the result could make possible next.
What Can Chemotherapy Do?
Chemotherapy is systemic treatment. Its job depends on what the disease needs now.
Treatment may aim to shrink cancer, slow or stop growth, control disease throughout the body, reduce symptoms or change a barrier that is preventing another treatment.
That goal should be clear before treatment begins, because it determines what counts as a useful response.
Right Question What exactly are we asking systemic treatment to achieve in my case?
First-Line Treatment
First-line means the first systemic treatment chosen for the current disease situation.
For many people with unresectable or metastatic biliary tract cancer, gemcitabine and cisplatin are combined with an immune checkpoint inhibitor as a current first-line approach.
Regimen choice can depend on disease setting, health, previous treatment, kidney and liver function, access and other clinical factors.
Molecular profiling should also be considered early, because tumour biology can affect later treatment choices.
Right Question Why is this the right first systemic treatment for me, and what other information do we need now to protect later options?
What Comes Next?
The next treatment should not be chosen automatically from a chemotherapy list.
When first-line treatment is no longer the best option, the next decision should consider the whole treatment landscape.
That may include another chemotherapy regimen, targeted therapy based on tumour biology, immunotherapy in selected situations, Interventional Radiology, radiation, clinical trials or reassessment for surgery.
FOLFOX is an established subsequent-line chemotherapy option, but it is one option within that wider decision.
Right Question Before choosing the next chemotherapy, have we reviewed my biology, local treatments, trials and whether surgery should be reconsidered?
Is It Working?
Starting treatment creates a new question: what is the cancer actually doing now?
Scans, symptoms, blood tests and sometimes tumour markers provide measurements of treatment response.
These measurements should be interpreted together. A single number or scan description is not the whole biology.
The important decision is whether treatment is achieving the job it was given and what that result changes next.
Right Question What evidence tells us how the cancer is responding, and what does that response change about the plan?
Dose, Side Effects & Staying on Treatment
The goal is not simply to receive the largest possible dose. The goal is to deliver useful treatment while preserving the ability to continue.
Side effects, blood counts, kidney function, liver function and general physical condition can all affect treatment delivery.
Dose reductions, delays or schedule changes may sometimes be used to manage toxicity and make treatment sustainable.
The consequence of any change should be explained, rather than treating a dose adjustment as either automatically good or automatically bad.
Right Question Why is the dose or schedule being changed, what are we trying to protect, and how will we judge whether treatment remains effective?
Can Response Change the Plan?
A good response should not simply produce the instruction “continue treatment”.
If tumour burden falls, disease elsewhere is controlled or a technical barrier changes, a treatment option that was previously unavailable may need to be reconsidered.
That may include surgery, radiation, Interventional Radiology or another local treatment.
Resectability is particularly important: a surgical assessment made before chemotherapy describes the disease before the response occurred.
Right Question Has my response changed anything enough that surgery or another treatment should now be reconsidered?
LOCAL TREATMENT
Radiation Therapy
Radiation concentrates treatment on a defined tumour or area rather than treating the whole body.
The important decision is not simply whether radiation can be given. Define the target, understand what radiation needs to achieve, protect the surrounding healthy tissue and know what the result could change next.
What Can Radiation Change?
Radiation is a local treatment. Its job is defined by the particular tumour or area being targeted.
It may be used to control a tumour, reduce its size, treat a difficult local site, relieve symptoms or support another treatment strategy.
This is different from systemic treatment, which travels throughout the body.
The first question is therefore not simply “Can I have radiation?” It is “What local problem are we trying to change?”
Right Question What specific tumour or area are we targeting, and what do we need radiation to change there?
External Beam Radiation
External beam radiation directs radiation from outside the body toward a planned target inside it.
Imaging and treatment planning are used to shape where the dose goes and reduce unnecessary exposure to surrounding healthy tissue.
Different techniques may be used depending on the tumour, its movement, nearby organs and the dose required.
Right Question What external beam technique are you recommending, and why does it best fit my tumour and surrounding anatomy?
SBRT / SABR
SBRT concentrates a high degree of precision on a defined target.
It may be considered when the tumour can be accurately located and nearby healthy structures can be adequately protected.
Its usefulness therefore depends on anatomy, tumour size, location and the treatment goal.
CyberKnife is one technology that can be used to deliver stereotactic radiation. It is not a separate treatment goal.
Right Question Is my tumour suitable for SBRT or SABR, what are we trying to achieve with it, and which nearby structures limit the dose?
Photon vs Proton Radiation
Both can deliver radiation to a tumour. The important difference is how the dose is distributed through the body.
Photon radiation deposits dose as it enters, through the target and beyond it.
Proton therapy can sometimes reduce the amount of radiation delivered beyond the target.
That does not make proton therapy automatically better. Its value depends on whether that dose difference meaningfully protects important healthy tissue in your particular anatomy.
Right Question Would proton therapy meaningfully reduce dose to important healthy tissue compared with the photon plan available to me?
Chemoradiation
Chemoradiation combines systemic medicine with radiation during the same treatment strategy.
In some settings, chemotherapy is used alongside radiation to increase the effect of radiation on the targeted cancer.
The reason for combining them should be clear, because it can also change toxicity and treatment burden.
Right Question Why are chemotherapy and radiation being combined in my case, and what treatment advantage are we trying to gain?
Can Radiation Change the Plan?
If radiation changes the local barrier, the treatment decision may need to change too.
In selected situations, radiation may control or reduce local disease that was limiting surgery or another local treatment.
But a new opportunity only exists if the original barrier changes enough for the next treatment to become technically and biologically appropriate.
That means a meaningful response should trigger reassessment, not simply continuation of the old plan.
Right Question If radiation works well, what treatment decision will be reassessed, and could surgery or another local treatment become possible?
Radiation for Symptom Control
Sometimes the job of radiation is to treat the problem a particular tumour is causing.
Radiation may be used to help control pain, bleeding or pressure on nearby structures.
In that setting, the treatment goal is different from attempting to change overall disease throughout the body.
The expected benefit and timeframe should therefore be made clear.
Right Question What symptom are we trying to improve, and how will we know whether radiation has helped?
Treatment Terms
Loading…
FIND THE BIOLOGY
Precision Medicine
Precision Medicine looks for biological information inside the cancer that could change a treatment decision.
Testing is not the outcome. The outcome is understanding what was tested, what was found, what is still missing, and whether any result creates an option.
Confirm the Diagnosis
Before matching treatment to biology, be clear about what cancer the tissue supports.
The pathologist combines the appearance of the tumour, immunohistochemistry, the clinical picture and other available information to reach a diagnosis.
Markers such as CK7 and CK19 may support a biliary or pancreatobiliary pattern, but no single marker by itself proves cholangiocarcinoma.
The useful question is therefore whether the full pattern supports cholangiocarcinoma and what competing diagnoses were considered.
Right Question What evidence in my pathology supports cholangiocarcinoma, and what other possible primary cancers were considered?
Profile the Tumour
Genomic profiling reads the cancer for biological changes that may create a treatment opportunity.
The objective is not to produce the longest possible mutation list. It is to identify findings that alter treatment, create a clinical-trial option or change what needs to be investigated next.
Testing should be discussed early enough for the result to influence the treatment sequence.
Existing tumour tissue may be usable. Blood-based tumour DNA testing may also provide information in selected situations, particularly when tissue is limited.
Right Question Has my cancer had sufficiently broad molecular profiling, and will the results arrive early enough to influence my next treatment decision?
Find Treatment-Linked Alterations
Precision Medicine finds the biological signal. The next job is to determine whether that signal creates an option.
Different cholangiocarcinomas can contain different genomic alterations and protein changes.
Some findings may connect to an approved treatment, an off-label treatment discussion, a clinical trial or another research pathway.
The exact alteration matters. Finding the name of a gene is not automatically the same as finding a treatment target.
Right Question Which exact alterations were found, and does any one of them create a treatment or clinical-trial opportunity for me?
Check Immune Biology
Immune biomarkers look at different biological signals. They are not interchangeable tests.
Mismatch-repair proteins, microsatellite instability, tumour mutation burden and PD-L1 each measure different things.
Their value lies in understanding the exact result and whether that result changes an immunotherapy decision.
For mismatch repair, IHC commonly examines MLH1, PMS2, MSH2 and MSH6.
Right Question Which immune biomarkers have been tested, what were the exact results, and does any result change my treatment options?
Audit My Report
Do not stop at receiving the report. Audit what the report actually tells you.
A pathology or molecular report is evidence. The next job is to turn that evidence into treatment decisions.
The audit should answer:
- What was tested?
- What was found?
- What was not tested?
- Was the sample adequate?
- Which findings are treatment-linked?
- Which findings may create a clinical-trial option?
- What result needs follow-up or confirmation?
- What information is still missing?
This is where the report stops being a document and becomes a decision tool.
Right Question Can someone show me, in one place, what was tested, what was found, what is missing and exactly which findings change my options?
What If Something Is Missing?
A missing result is not always the end of the pathway. First understand why the information is missing.
Existing stored tissue may still be usable. If tissue is insufficient, blood-based testing may add information. In some situations, obtaining new tissue may also be considered.
A negative blood test does not necessarily prove that the tumour contains no relevant alteration.
Likewise, “nothing actionable found” can mean different things: no relevant finding was identified, the sample was limited, or the test did not cover everything now considered important.
As treatment and the cancer change, repeat molecular testing may sometimes provide new information.
Right Question What information are we still missing, why is it missing, and what is the best way to obtain it while the result can still change a decision?
Treatment Terms
Loading…
MATCH THE BIOLOGY
Targeted Therapy
Targeted Therapy uses a treatment designed to act on a specific biological feature of the cancer.
Precision Medicine finds the biological finding. Targeted Therapy asks whether that exact finding can now be turned into a treatment opportunity.
What Is Targeted Therapy?
Think of the cancer as depending on particular biological signals. Targeted Therapy tries to interfere with one of those dependencies.
A cancer cell may depend on an altered gene, abnormal protein or growth pathway that helps it survive or continue growing.
A targeted treatment is designed around that biological feature.
That is why testing comes first. The treatment only becomes relevant when the matching target or alteration has been identified.
Right Question What biological feature has been found in my cancer, and is there a treatment designed to act on it?
Is My Finding Actionable?
Finding an alteration and finding a treatment opportunity are not the same thing.
Molecular reports can contain many findings. Some help explain the cancer but do not currently change treatment.
A finding becomes actionable when it creates a real next step, such as a matched treatment, another treatment pathway or a clinical trial.
The level of evidence and treatment access may also differ between findings.
Right Question Does this finding change what I can actually do next, and what treatment or trial does it connect to?
The Exact Alteration Matters
The name of the gene is only the beginning. The exact biological change determines what it means.
A fusion, mutation, amplification or protein overexpression can represent different biological findings.
Even within one gene, different alterations may connect to different treatments or different clinical trials.
KRAS is a clear example. KRAS G12D, G12C, G12V and other variants are not interchangeable.
HER2 is another example. Protein expression, gene amplification and mutation are different results.
Right Question What is the exact alteration on my report, rather than only the name of the gene?
Treatment-Linked Targets
Different biological findings can lead to different treatment pathways.
The important job is to match the exact result to the treatment evidence relevant to that result.
FGFR2
FGFR2 fusions or rearrangements can create an FGFR-targeted treatment pathway in selected cholangiocarcinomas.
IDH1
An IDH1 mutation can create an IDH1-targeted treatment pathway.
HER2
HER2 findings need to be interpreted by the exact type and strength of the result.
BRAF V600E
The exact BRAF alteration matters. BRAF V600E is the treatment-linked finding represented here.
NTRK Fusion
NTRK fusions are uncommon but can create a specific matched-treatment pathway when present.
RET Fusion
A RET fusion can create a matched-treatment pathway when it is identified.
KRAS
KRAS is not one target. The exact mutation determines which treatment or trial opportunities may be relevant.
Right Question Which exact treatment is linked to my exact alteration, and what evidence supports using it in my situation?
Where Does Targeted Therapy Fit?
Finding a matched treatment does not by itself tell you when it should be used.
The treatment sequence can depend on the disease setting, treatments already received, the evidence supporting the matched therapy, access and the patient's condition.
A targeted treatment may therefore be highly relevant without automatically being the next treatment.
This is another reason molecular testing should happen early. The result can be known and protected before the decision point arrives.
Right Question If this treatment matches my cancer, when is the best point in my treatment pathway to use it?
Resistance & Re-Testing
Cancer biology can change while it is being treated.
A targeted treatment places pressure on the cancer. Over time, surviving cancer cells may develop or select biological changes that allow growth to continue.
When a targeted treatment stops working, tissue or blood-based molecular testing may sometimes help identify what has changed.
That information may reveal another treatment, a clinical trial or a new biological question.
Right Question If this targeted treatment stops working, should we test again to understand what changed and whether another option has appeared?
Treatment Terms
Loading…
USE THE IMMUNE SYSTEM
Immunotherapy
Immunotherapy can help immune cells remain active against cancer by blocking selected signals that normally slow or stop an immune response.
Think of the immune system as a security team. Checkpoint immunotherapy does not simply make the team stronger. It removes a selected stand-down signal that may be holding it back.
What Can Immunotherapy Do?
Immunotherapy changes the interaction between the cancer and the immune system.
T cells can recognise abnormal cells and attack them, but the immune system also contains checkpoints that reduce or stop immune activity.
Cancer can take advantage of these normal control systems. Checkpoint inhibitors block selected signals so immune cells can remain active for longer.
The treatment therefore does not directly attack the cancer in the same way as chemotherapy. It changes the conditions under which the immune system can respond.
Right Question What immune pathway is this treatment trying to unblock, and what do we expect the immune system to do differently afterwards?
Which Checkpoint Is Being Targeted?
Immune checkpoints are different brakes in the immune system. Different drugs release different brakes.
PD-1 and PD-L1 form one checkpoint pathway. When PD-L1 engages PD-1, T-cell activity can be reduced.
CTLA-4 is another checkpoint. It acts earlier in the process of T-cell activation.
Blocking one checkpoint is therefore biologically different from blocking another, and checkpoint pathways can sometimes be targeted in combination.
Right Question Is my treatment blocking PD-1, PD-L1, CTLA-4 or more than one checkpoint, and why was that pathway chosen?
Which Biomarkers Matter?
Biomarkers are clues about the cancer's immune biology. They do not all measure the same thing.
dMMR describes failure of the DNA mismatch-repair system. MSI-H describes a molecular pattern that can result from that repair failure.
TMB estimates how many mutations have accumulated across the tumour. PD-L1 testing measures expression of one checkpoint-related signal.
No single biomarker explains every immunotherapy response. The useful question is what each result means in your treatment context.
Right Question Have dMMR, MSI-H, TMB and PD-L1 been considered, what were the exact results, and does any result change my immunotherapy options?
Which Checkpoint Inhibitor?
The drug name tells you which immune brake is being targeted.
Pembrolizumab and nivolumab block PD-1. Durvalumab blocks PD-L1. Ipilimumab blocks CTLA-4.
Nivolumab and ipilimumab can also be used together in situations where two checkpoint pathways are being targeted.
The important question is not simply which drug is being given. It is why that checkpoint strategy fits the treatment plan.
Right Question Which checkpoint inhibitor am I receiving, which brake does it release, and why does that strategy fit my cancer?
Why Do Responses Differ?
Releasing a brake only helps if an effective immune response can actually follow.
T cells still need to recognise abnormal cells, reach the tumour, remain functional inside the tumour environment and stay active long enough to do useful work.
The cancer itself is also heterogeneous. Different cells within the same cancer may not interact with the immune system in exactly the same way.
This is why response cannot be predicted from one simple marker.
Right Question What features of my cancer support or limit the possibility of an effective immune response?
Is It Working?
Immunotherapy still needs to produce a measurable clinical result.
Imaging, symptoms, blood tests and the overall clinical picture help show whether disease is responding, stable or progressing.
The measurement is evidence of what may be happening. It is not the cancer biology itself.
A meaningful response should also trigger the next question: has that response created another treatment opportunity?
Right Question What evidence tells us whether immunotherapy is working, and does the response change what treatment should be considered next?
What If Immunotherapy Stops Working?
Cancer is a changing population of cells, not one permanently fixed target.
Treatment creates selection pressure. Cells that survive may differ biologically from those that were removed or controlled.
The surviving cancer may become less visible to T cells, rely more heavily on another checkpoint or develop a tumour environment that suppresses immune activity.
Progression therefore creates another biological question: what changed, and does that change create another option?
Right Question If immunotherapy has stopped working, what might have changed biologically and does that create another treatment or trial opportunity?
Treatment Terms
Loading…
PROTECT FUTURE OPTIONS
Clinical Trials
Clinical trials can provide access to treatments, combinations and strategies that are still being tested.
Do not wait until the current road ends before looking for the next one. A trial that fits today may no longer fit later if treatment history, disease, organ function or physical condition changes.
Why Trials Belong in the Treatment Plan
A clinical trial is a treatment opportunity, not simply a last resort after every other option has gone.
Trials test treatments under a defined research protocol. They may investigate a new medicine, combination, procedure or different way of using an existing treatment.
Some trials may become relevant only after a particular treatment. Others may require that certain treatments have not yet been given.
That means trial searching belongs alongside treatment planning, even when a trial is not needed today.
Right Question What clinical trials should we know about now so that treatment today does not unnecessarily close an opportunity I may need later?
Find & Match a Trial
Finding trials is a matching problem: what does the trial require, and what does your cancer and treatment history show?
A useful search goes beyond the word “cholangiocarcinoma”.
Tumour location, stage, previous treatments, biomarkers, molecular alterations, country and ability to travel can all change which trials fit.
Biomarker-led and basket trials can also identify opportunities by shared biology rather than only by where the cancer began.
Because trials open, close and change, the search should be repeated at important treatment decision points.
Right Question Has my trial search used both my diagnosis and my molecular profile, and when will the search be repeated?
Protect Eligibility
Finding the trial is not enough. You still need to meet its entry rules.
Eligibility can depend on cancer type, molecular findings, disease stage, previous treatment, organ function and physical performance.
Some criteria describe what must be present. Other criteria describe what excludes a patient.
Eligibility can therefore change over time. A treatment given today, declining organ function or deterioration in physical condition may alter whether entry remains possible later.
Right Question What could make me eligible or ineligible for this trial, and what can we protect now to keep the option open?
Understand What Is Being Tested
Before judging a trial, understand the question the researchers are trying to answer.
Early-phase trials often focus on dose, safety, tolerability and early evidence of anti-cancer activity.
Later phases generally gather more evidence about treatment activity and may compare a new approach with an established treatment.
A trial may also have different study arms, randomisation or other design features that affect which treatment you actually receive.
The phase number alone does not tell you whether a trial is appropriate for you. What is already known about the treatment matters.
Right Question What is already known about this treatment, what is this trial still trying to learn, and what treatment would I actually receive?
Trial or Established Treatment?
Compare two treatment opportunities, not simply “proven” versus “experimental”.
Established treatment has more evidence behind it. A trial may provide access to a newer strategy with different uncertainties and possible benefits.
The comparison should include what each option is trying to achieve, what evidence supports it, likely risks, what treatment would actually be received and what opportunity may be gained or lost by choosing one first.
Treatment sequence matters. Entering a trial may affect later options, while taking another treatment first may affect trial eligibility.
Right Question What do I gain, risk or potentially give up by choosing this trial now instead of the established option?
Cost, Travel & Access
Finding the treatment is only useful if you can actually reach it.
A trial may cover the study treatment and some trial-related tests, but that does not mean every cost is covered.
Travel, accommodation, carers, time away from work, visas and repeated hospital visits can become part of the treatment decision.
Treatment Overseas
If an important treatment is not available in Australia, the Medical Treatment Overseas Program may be relevant for eligible Australians who meet its requirements.
New Zealand: Pharmac NPPA
If a medicine is not normally funded for your situation in New Zealand, an authorised prescriber may be able to ask Pharmac to consider individual funding through the Named Patient Pharmaceutical Assessment process.
Compassionate or Special Access
If the treatment exists but trial entry is not possible, another access pathway may sometimes be explored through the treating doctor, company and applicable regulatory process.
Right Question If this is the treatment opportunity we want to pursue, what practical, financial or access barriers stand between me and receiving it, and which of those barriers can be solved?
Before I Join
Consent should mean understanding the decision, not simply signing the document.
Know what treatment you may receive, what is already known, what remains uncertain, the important risks, how often you must attend and which tests or procedures are required.
Understand whether there are different study arms, whether allocation is randomised and whether a placebo could be involved.
Also understand what happens afterwards. A trial needs an exit plan as well as an entry plan.
Right Question If I join this trial, what happens if it works, what happens if it does not, and which treatment options remain afterwards?
Treatment Terms
Loading…
PROTECT TREATMENT CAPACITY
Integrative
Integrative care sits alongside cancer treatment. Its job is to support the patient while treatment does its job.
Think of cancer treatment as a load the body has to carry. Nutrition, strength, recovery and symptom management can help protect the capacity needed to keep treating.
What Is Integrative Care?
Loading…
Nutrition
Loading…
Exercise & Strength
Loading…
Sleep & Recovery
Loading…
Loading…
Manage Treatment Burden
Loading…
Supplements & Interactions
Loading…
Use Integrative Care Safely
Loading…
REDUCE THE BURDEN
Palliative Options
Palliative care focuses on reducing symptoms, protecting function and helping you live as well as possible alongside cancer treatment.
Think of palliative care as another specialist team. Its job is to reduce the load created by the cancer and its treatment while the wider treatment plan continues.
What Is Palliative Care?
Loading…
Can I Still Have Active Treatment?
Loading…
Is This End-of-Life Care?
Loading…
Control Symptoms
Pain
Loading…
Nausea & Appetite
Loading…
Fatigue & Function
Loading…
Itching & Bile Obstruction
Loading…
Breathlessness
Loading…
When Should Palliative Care Begin?
Loading…
Family, Caregivers & Finding Care
Support for Family & Caregivers
Loading…
Find Palliative Care
Loading…
REMOVE PRACTICAL BARRIERS
Financial, Travel & Family Support
Cancer creates practical barriers as well as medical ones. Cost, distance, work and caring responsibilities can all affect whether a treatment option can actually be used.
Treatment only works if you can reach it and keep going. Identify the practical barrier early, then find the support that can reduce it.
Paying for Care
Do not assume the financial burden of treatment has to be carried alone.
Treatment can create direct medical costs as well as indirect costs from travel, time away from work and changes in family income.
Financial Assistance
Loading…
Medicare Safety Net
Loading…
Right Question Which treatment-related costs can be reduced, reimbursed or supported before they become a barrier?
Travel & Accommodation
Distance should be treated as a practical problem to solve, not automatically as a reason an option cannot be pursued.
Specialist surgery, clinical trials, radiation and other treatment may require care outside your local area.
Travel Assistance
Loading…
Accommodation Support
Loading…
Right Question If the treatment I need is away from home, what assistance can help me reach it and stay near the treating centre?
Income, Work & Insurance
Cancer can affect income before people realise what financial protections or benefits they already have.
Legal, Workplace & Financial Help
Loading…
Superannuation & Insurance
Loading…
Right Question What workplace rights, insurance, superannuation or financial support should I investigate now?
Carer Support
The patient's treatment capacity can depend heavily on the person carrying the practical load beside them.
Carer Payment
Loading…
Carer Allowance
Loading…
Carer Gateway
Loading…
Family & Carer Support
Loading…
Right Question What support is available for the person who is helping me get through treatment?
Help at Home
Preserving treatment capacity can also mean reducing the ordinary workload waiting at home.
Practical Help at Home
Loading…
Right Question Which everyday tasks are now consuming energy that would be better protected for treatment and recovery?
Where Do I Start?
You do not need to know every support program before asking for help.
Start with the practical problem: money, travel, accommodation, caring, work or help at home. Then identify the service best placed to solve it.
Cancer Council Support
Loading…
Right Question Who can help me identify the support services that match the practical problems my family is facing now?
